Home  >  Research  >  Labs  >  Cancer Program  >  LABORATORY FOR CANCER MEDICINE

RESEARCH OVERVIEW

The Laboratory for Cancer Medicine team is driving a program of research that aims to discover new ways of treating cancer. The initial focus was on hormone dependent cancers, such as breast and prostate, but in recent years has expanded to include other cancers which may be associated with a poor prognosis – liver, colon, melanoma and head and neck. Our goal is to discover ways to abrogate the key pathways driving the growth of these tumors, with a view to translating some of these discoveries into new therapies.

From the mechanistic point of view, we have had a long-term interest in RNA biology and human disease, and this has led to discoveries of novel RNA-binding proteins that are involved in regulating hormone action in breast and prostate cancer. One of these, SLIRP, is a repressor of nuclear receptor hormone action that we are exploring in the context of prostate and colon cancer. Several other novel regulators of hormone action have been identified (eg. PACT), which are being investigated using genome-wide approaches in the context of their role as activators of prostate cancer growth.

Our interest in RNA biology was a natural fit for developing significant focus in microRNAs and cancer. microRNAs are short non-coding RNAs that play central roles in regulating normal cell growth. They offer great promise in cancer biology, as they present new avenues for diagnostics and therapeutics. Our studies have resulted in the discovery of several “tumor suppressor microRNAs” that suppress key signalling pathways in poor prognostic tumors, such as head and neck, melanoma and liver cancer. One of these, microRNA-7 or miR-7, acts a potent suppressor of cancer cell proliferation and invasion by targeting the EGF-receptor (EGFR) pathway. In parallel with our work to explore the functional biology of miR-7 in EGFR-driven tumors (head and neck, liver, prostate, glioma) using genome-wide approaches and preclinical models, we have established a spin-out company, miReven, which is focused on developing miR-7 as a potential ‘miR replacement therapy” for these cancers which we hope to move into early phase clinical trials in the forthcoming years. 

Professor Peter Leedman AO

Professor Peter Leedman AO

Cancer Medicine (Institute Director)

Read more

LATEST NEWS

Perkins researchers Prof Jonas Nilsson and Dr Peter Lau at lab bench with equipment

WA melanoma research featured at global Oncology congress

Breakthrough research from the Harry Perkins Institute of Medical Research that explores possible new treatments for melanoma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Medical oncologist and physician researcher Dr Peter Lau will present a summary on the CHARLI (CHeckpoint And RANK-L Inhibition) trial,…

Read More
Dr Ankur Sharma in front of MRI image at Harry Perkins Institute of Medical Research

New liver cancer blood test gets $2.5m research funding boost

Predicting relapse for one of the world's deadliest cancers. Perth cancer researchers are on track to improve the outcomes of patients with the most common type of primary liver cancer. Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. Patients typically suffer a high rate of treatment failures.…

Read More
people in lab coats inside a cancer laboratory

ACRF Centre for Advanced Cancer Genomics opens in Perth

Latest technology analyses WA cancer patient tumours. The Australian Cancer Research Foundation (ACRF) Centre for Advanced Cancer Genomics, housing the next generation DNA sequencing technology, was opened today at the Harry Perkins Institute of Medical Research by the Federal Member for Curtin, Ms Kate Chaney. ACRF CEO, Kerry Strydom, in…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS